Devopharma ApS: Financial statements 2024
CVR: 38968254
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Devopharma ApS (CVR 38968254) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2024 report amounted to DKK 28,125. The solvency ratio was 28.1%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 28,125
- Total Assets
- DKK 100,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -3 t. | -3 t. | 28 t. | 0 |
| 2023 | - | -3 t. | -3 t. | 31 t. | 0 |
| 2022 | - | -3 t. | -3 t. | 34 t. | 0 |
| 2021 | - | -3 t. | -3 t. | 38 t. | 0 |
| 2020 | - | -3 t. | -3 t. | 41 t. | 0 |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Devopharma ApS has published its annual report for 2023. Gross profit came to DKK -3,125, and the net result was DKK -3,125.
About Devopharma ApS
Devopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company's owners include JARCO HOLDING ApS, HN HOLDING 2010 ApS and Friendly Holding ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.